Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
broad-spectrum adenovirus vector COVID-19 vaccine
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The broad-spectrum adenovirus vector COVID-19 vaccine is a preclinical vaccine candidate developed by AIM Kanghuai, a subsidiary of AIM Vaccine. This vaccine utilizes an adenoviral vector platform to deliver genetic material encoding SARS-CoV-2 antigens into host cells. It is specifically designed to elicit a broad immune response that provides protection across multiple variants of the virus. By inducing both neutralizing antibodies and cellular immune responses against the viral spike protein, the vaccine aims to provide robust and durable defense against the evolving landscape of SARS-CoV-2 strains.
- Other names
- COVID-19 adenovirus vector vaccine-AIM Kanghuai-adenovirus vector vaccine-COVID-19 (broad-spectrum, multiple variants)broad-spectrum adenovirus vector COVID-19 vaccine (multiple variants)AIM Kanghuai adenovirus vector COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on broad-spectrum adenovirus vector COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on broad-spectrum adenovirus vector COVID-19 vaccine.